Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Astellas Pharma Inc.    4503   JP3942400007


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Astellas Pharma Inc. : - Notice Regarding Continuation of the Performance-linked Stock Compensation Scheme

05/21/2020 | 10:58am EST

TOKYO - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., 'the Company') today announced that the meeting of the Board of Directors held today passed a resolution of the details of the incentive plan ('Plan') to be implemented in fiscal year 2020 based on the Performance-linked Stock Compensation Scheme ('Scheme') for the Company's Directors (excluding outside Directors and Directors who are Audit & Supervisory Committee Members; hereinafter 'Directors') as described below.

Objective for the Scheme

The Scheme is a medium- to long-term-based incentive plan, for the Directors that is highly transparent and objective, and closely linked with the Company's enterprise and shareholder value with the aim of promoting management focused on increasing enterprise and shareholder value over the medium- to long-term.

The Scheme adopts a structure called the executive compensation BIP (Board Incentive Plan) trust ('BIP Trust'). BIP Trust is an executive incentive plan modeled on Performance Share and Restricted Stock systems in the U.S.The BIP Trust acquires the Company's shares and conducts a 'delivery of the Company's shares' (as set forth in 3. (5) below; hereinafter the same) to the Directors based on the level of growth of enterprise and shareholder value, etc.

The Structure of the BIP Trust

Based on the Scheme, the Company shall resolve on the implementation and content of the Plan for fiscal year 2020 at the meeting of the Board of Directors.

The Company will put money in trust, to establish the BIP Trust, which will be the trust in which the beneficiaries shall be the Directors who have satisfied the beneficiary conditions ('Trust'). The money entrusted in the Trust shall be within the scope of approval of the 14th Term Annual Shareholders Meeting.

The Trust, in accordance with the instructions of the trust administrator, will use the money entrusted in 2) to acquire the Company's shares on the stock market.

Dividends for the Company's shares in the Trust will be paid in the same way as with other shares of the Company.

Voting rights are not to be exercised on the Company's shares within the Trust throughout the trust period.

During the trust period, beneficiaries will receive delivery of the Company's shares in accordance with the Company's Share Delivery Policy.

In the event that residual shares remain at the expiration of the trust period mainly due to the extent to which enterprise and shareholder value have achieved growth during the trust period, the Trust will continue to be used as an incentive plan based on the Scheme by making changes to the trust agreement and additional entrustments (1), or otherwise a gratis transfer of these residual shares will be made from the Trust to the Company, and upon acquiring these shares the Company plans to implement the cancellation of them by resolution of the Board of Directors.

Upon conclusion of the Trust, the residual assets remaining after allocation to the beneficiaries are to belong to the Company within the scope of the reserve fund for trust expenses after deductions for stock purchases from trust money. In the event that there remain residual assets beyond the scope of the reserve fund for trust expenses, such assets are to be donated to an organization having no relationship of interest with the Company or Directors and Corporate Executives of the Company.

Details of the Plan

Overview of the Plan

The Plan is an incentive plan, under which delivery of the Company's shares will be conducted during the three-year period from the fiscal year ending March 31, 2021 to the fiscal year ending March 31, 2023 ('Applicable Period'), based on the level of growth of enterprise and shareholder value, etc. The Company intends to continue implementing incentive plans which are similar to the Plan in each year in and after the following fiscal year by establishing new BIP Trusts, or by making changes or additional entrustments to the existing BIP Trusts that have expired. The details of incentive plans put into effect next fiscal year or later shall be determined at the appropriate time by resolution of the Board of Directors.

Individuals eligible under the Plan (Beneficiary Conditions)

The Directors who are in office as of July 1, 2020 ('Eligible Individuals') will, in principle, receive delivery of a certain number of the Company's shares based on the points provided for below in (4) subject to the condition that the Beneficiary Conditions set forth below are satisfied.

About Astellas

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products.

Cautionary Notes

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.


Tel: +81-3-3244-3201

Fax: +81-3-5201-7473

(C) 2020 Electronic News Publishing, source ENP Newswire

01/14ACTINIUM PHARMACEUTICALS : and Astellas Announce Research Collaboration Focused ..
01/06ASTELLAS PHARMA INC. : - FDA Accepts for Priority Review the New Drug Applicatio..
2020ASTELLAS PHARMA : FDA Lifts Clinical Hold for Audentes Therapeutics' AT132 Trial
2020ASTELLAS PHARMA : Reports XOSPATA in Combination with Azacitidine Did Not Meet E..
2020ASTELLAS PHARMA : Supports Recommendations of Task Force on Climate-related Fina..
2020ASTELLAS PHARMA INC. : - Expansion of the Domestic Logistics Platform for Pharma..
2020VIATRIS : Astellas and Viatris Announce Termination of Co-promotion, Succession ..
2020Japan shares slip for third day; all eyes on U.S. stimulus debate
2020Japanese shares slip back as investors look to U.S. stimulus debate
2020Astellas Pharma, Viatris Pharmaceuticals Japan to End Joint Sales Promotion o..
More news
Sales 2021 1 272 B 12 253 M 12 253 M
Net income 2021 181 B 1 744 M 1 744 M
Net cash 2021 440 B 4 239 M 4 239 M
P/E ratio 2021 17,0x
Yield 2021 2,50%
Capitalization 3 130 B 30 155 M 30 153 M
EV / Sales 2021 2,11x
EV / Sales 2022 1,93x
Nbr of Employees 15 883
Free-Float 99,2%
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | 4503 | JP3942400007 | MarketScreener
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 2 268,18 JPY
Last Close Price 1 685,00 JPY
Spread / Highest target 114%
Spread / Average Target 34,6%
Spread / Lowest Target -2,08%
EPS Revisions
Managers and Directors
Kenji Yasukawa President, CEO & Representative Director
Yoshihiko Hatanaka Chairman
Naoki Okamura Representative Director & Vice President
Tomokazu Fujisawa Director
Hiroko Sakai Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON3.92%430 552
ROCHE HOLDING AG3.06%308 615
NOVARTIS AG2.73%220 726
MERCK & CO., INC.-1.00%204 882
PFIZER INC.-0.71%203 159